###### Strengths and limitations of this study

-   This population-based study demonstrates a real-world practice patterns in sedative, analgesic, neuromuscular blocking agent and antipsychotic use among elderly patients in the intensive care unit using a nationwide Korean database.

-   The administration of these medications was analysed by the duration of mechanical ventilation, patient age and annual trends.

-   Since this study analysed a claims database, it was not able to assess clinical severity scores.

-   The determination of causal relationship is limited since it was a cross-sectional study.

Introduction {#s1}
============

Sedation and pain management are necessary to both reduce discomfort and treat underlying diseases, in mechanically ventilated intensive care unit (ICU) patients. Clinical practice guidelines for the management of pain, agitation, sedation and delirium in adult patients have been developed and have improved general understanding of the importance of sedation and pain medication in critically ill patients.[@R1] Elderly patients are prone to adverse drug reactions due to altered pharmacokinetics and pharmacodynamics as well as underlying diseases. Patients over 65 years of age comprise up to 50% of all ICU admissions[@R3] and patients over 80 years of age comprise 18% of critical care cases.[@R4] Although benzodiazepines, opioids and antipsychotics are commonly used for sedation and treatment of pain and delirium in critical care, these medications are strongly recommended to avoid in geriatric populations due to the risk of adverse drug events including delirium and cognitive impairment, based on the Beers or Screening Tool of Older Persons\' Potentially Inappropriate Prescriptions criteria.[@R5] These criteria have been applied in community-dwelling older adults and have recently been applied to hospitalised elderly patients.[@R7] However, it is difficult to apply these criteria to critically ill patients with diverse urgent situations. Recent clinical guidelines have reinforced immobility and sleep issues but there were few considerations regarding proper choice, practical doses and administrative routes of sedative, analgesics and adjunctive therapies in elderly patients. Available data on the estimated real-life use of medications for pain and sedation considering their potential complications in elderly ICU patients have been lacking.[@R2] We conducted a population-based cross-sectional study using a nationwide Korean database to provide real-world data regarding the current practices of critical care medication use among mechanically ventilated elderly patients, with a focus on the use of sedatives, analgesics, neuromuscular blocking agents (NMBAs) and antipsychotic medications compared with current guidelines for adult patients. We analysed the patterns of medication use according to the duration of mechanical ventilation (MV), patient age and annual trends and assessed patient factors related to the use of sedatives and analgesics in elderly patients.

Methods {#s2}
=======

Data source and study population {#s2a}
--------------------------------

We performed a cross-sectional study using the national claims database for the period from 2012 to 2016. Most of the population in Korea is covered by national insurance. The aged patients' sample (APS) data used in this study was a 20% stratified sample directly proportional to the age and sex of Korean elderly patients (aged 65 years or older) served from the Health Insurance Review and Assessment Service (HIRA-APS-2016-0064). The database includes information regarding diagnoses made in accordance with the International Classification of Diseases 10th revision (ICD-10), institutional information, patient characteristics, medication prescriptions, medical procedures and healthcare expenditures. Critically ill patients who underwent MV in the ICU were eligible for this study ([figure 1](#F1){ref-type="fig"}). We only included patients admitted to the ICU in the general or tertiary hospital, as determined using reimbursement codes. We excluded patients who underwent surgical procedures under general anaesthesia in operating rooms due to differences in the usage of analgesics for surgical pain. In cases of patients with multiple ICU admissions, only the first admission was included in our analyses.

![Flow diagram of patient selection. We selected elderly patients who underwent mechanical ventilation in the ICU based on reimbursement and procedure codes. Patients who underwent surgeries under general anaesthesia were excluded. ICU, intensive care unit.](bmjopen-2018-026605f01){#F1}

Study medications {#s2b}
-----------------

We assessed the use of sedatives, analgesics including opioids, NMBAs and antipsychotics. In total, 124 medications were assessed (32 sedatives, 10 opioid analgesics, 44 non-opioid analgesics, 12 NMBAs and 26 antipsychotics). The detailed medications included in the analyses are described in (online [supplementary table 1](#SP1){ref-type="supplementary-material"}). The sedatives included benzodiazepines (eg, midazolam and lorazepam), propofol, ketamine, etomidate and barbiturates. The analgesics included opioids and non-opioid analgesics administered as adjunctive therapy. Fentanyl, morphine, remifentanil, sufentanil and pethidine were the representative opioid analgesics. The daily dose of opioids was calculated based on oral morphine-equivalent doses (MEDs).[@R9] We also classified opioids by route of administration (intravenous, enteral, or topical). We defined non-opioid analgesics as acetaminophen (AAP), non-steroidal anti-inflammatory drugs (NSAIDs) and anticonvulsants (eg, gabapentin and carbamazepine) used to treat neuropathic pain.[@R1] As NMBAs, we included rocuronium, vecuronium and cisatracurium. Antipsychotic medications included both conventional (eg, haloperidol) and atypical (eg, risperidone and quetiapine) antipsychotics.
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Patient characteristics {#s2c}
-----------------------

We identified demographic characteristics (age, sex), route of admission, primary disease and comorbidities. We used ICD-10 codes to identify primary diseases and comorbidities. The primary diseases included cardiac disease, cerebrovascular disease, chronic pulmonary disease, gastrointestinal disease, liver disease, malignancy, pneumonia, poisoning, renal disease, sepsis and trauma. The chronic comorbid conditions included Charlson Comorbidity Index,[@R11] hypertension and transplantation (online [supplementary table 2](#SP1){ref-type="supplementary-material"}). In addition, we assessed continuous renal replacement therapy (CRRT), duration of MV, length of ICU stays, length of hospitalisation and in-hospital mortality. In-hospital mortality was identified as the total mortality reported outcomes at the time of hospital discharge.

Statistical analysis {#s2d}
--------------------

We performed subgroup analyses by the duration of MV, patient age and annual trends. We categorised the study population into three groups based on MV duration (\<48 hours, 48 hours to \<7 days, or 7 days or more). The characteristics of the study population and patterns of medication use were assessed based on MV subgroups. Three age groups were used (65≤age\<75 years, 75≤age \<80 years, or 80 years or more), according to the distribution of our population. The annual trends from 2012 to 2016 regarding medication use in critically ill elderly patients with MV were analysed.

Continuous variables were presented as means and SD for age and as median values with an IQR for other variables. Categorical variables were presented as frequencies and proportion. In addition, the duration of use of each medication was presented as percentage person-days, which was calculated by dividing the days of medication use by the duration of ICU stay. Comparisons between groups were analysed by Pearson and Mantel-Haenszel Χ^2^ or Fisher's exact tests for categorical variables and analysis of variance or Kruskal-Wallis tests for continuous variables. To assess factors associated with sedatives or opioids use, we estimated adjusted odds ratios and their 95% CIs using multivariable logistic regression models. P values\<0.05 were considered statistically significant. However, when comparing medication use according to MV duration, age group and annual trends, we applied a Bonferroni correction to correct for multiple comparisons: therefore, we considered p values\<0.0167 as statistically significant. Analyses were performed using SAS V.9.4.

Patients and public involvement {#s2e}
-------------------------------

This study was a cross-sectional analysis of a national sample claims database. The database is anonymised and served without identifiers of the study participants. The patients were not involved in designing or conducting this study. We intend to disseminate the results by paper publication in a journal.

Results {#s3}
=======

Patient demographics {#s3a}
--------------------

APS data from 2012 to 2016 shows that 1 58 656 patients (2.6%) were admitted to general or tertiary hospital ICUs. Among 36 598 patients with MV, we excluded those who underwent surgical procedures under general anaesthesia; subsequently, we analysed 22 677 patients in 267 ICUs of general (n=224) and tertiary (n=43) hospitals ([figure 1](#F1){ref-type="fig"}). Their mean age was 77.2 (±6.9) years and the proportion of male patients was greater than that of females. More than half of the patients were admitted through the emergency department. The median duration of MV was 4.1 days (IQR 2--10) and the in-hospital mortality rate was 57.0%. We categorised the study population into three groups by MV duration (\<48 hours, 48 hours to \<7 days and 7 days or more). The baseline characteristics of each group are described in [table 1](#T1){ref-type="table"}. There were no differences in the distributions of patients in age or time categories among the three groups of MV duration (p=0.08 and p=0.31, respectively). The proportions of men to women increased with longer MV duration. Pneumonia (19.3%) was the most common primary disease associated with admission to the ICU. The group with less than 48 hours of MV had a higher rate of cardiac disease (p\<0.01), cerebrovascular disease (p=0.04) and liver disease (p\<0.01); however, the group with longer MV duration (MV≥7 days) showed more chronic pulmonary disease, malignancy and pneumonia (p\<0.01). The group with longer MV also showed a higher rate of application of CRRT (p\<0.01). The median ICU and hospital stays increased with greater MV duration (p\<0.01).

###### 

Characteristics of critically ill elderly patients with mechanical ventilation

  ---------------------------------------------------------------------------------------------------------------
  Variables                      Total\          MV\<48 hours\    48hrs≤MV\<7days\   MV≥7 days\       P value\*
                                 (n=22 677)      (n=5480)         (n=8903)           (n=8294)         
  ------------------------------ --------------- ---------------- ------------------ ---------------- -----------
  Age (years), mean, SD          77.2 (6.9)      77.4 (7.0)       77.2 (6.8)         77.2 (6.8)       0.09

   65--69                        3345 (14.8)     822 (15.0)       1306 (14.7)        1217 (14.7)      0.08

   70--74                        5206 (23.0)     1217 (22.2)      2111 (23.7)        1878 (22.6)      

   75--79                        5813 (25.6)     1367 (24.9)      2258 (25.4)        2188 (26.4)      

   80--84                        4737 (20.9)     1128 (20.6)      1836 (20.6)        1773 (21.4)      

   85--89                        2598 (11.5)     685 (12.5)       1002 (11.3)        911 (11.0)       

   90-                           978 (4.3)       261 (4.8)        390 (4.4)          327 (3.9)        

  Year                                                                                                

   2012                          4642 (20.5)     1131 (20.6)      1782 (20.0)        1729 (20.8)      0.31

   2013                          4478 (19.7)     1087 (19.8)      1699 (19.1)        1692 (20.4)      

   2014                          4513 (19.9)     1071 (19.5)      1834 (20.6)        1608 (19.4)      

   2015                          4588 (20.2)     1105 (20.2)      1833 (20.6)        1650 (19.9)      

   2016                          4456 (19.6)     1086 (19.8)      1755 (19.7)        1615 (19.5)      

  Sex (Male)                     12 932 (57.0)   2938 (53.6)      5018 (56.4)        4976 (60.0)      \<0.01

  Admission route (emergency)    14 777 (65.2)   3631 (66.3)      5910 (66.4)        5236 (63.1)      \<0.01

  Charlson's comorbidity score   2 (1--4)        2 (1--4)         2 (1--4            2 (1--4)         \<0.01

  Primary diseases                                                                                    

   Cardiac disease               2902 (12.8)     935 (17.1)       1215 (13.7)        752 (12.8)       \<0.01

   Cerebrovascular disease       2670 (11.8)     674 (12.3)       1066 (12.0)        930 (11.2)       0.04

   Chronic pulmonary disease     1241 (5.5)      170 (3.1)        547 (6.1)          524 (6.3)        \<0.01

   Gastrointestinal              277 (1.2)       92 (1.7)         106 (1.2)          79 (1.0)         \<0.01

   Liver disease                 225 (1.0)       83 (1.5)         88 (1.0)           54 (0.7)         \<0.01

   Malignancy                    2224 (9.8)      477 (8.7)        796 (8.9)          951 (11.5)       \<0.01

   Pneumonia                     4366 (19.3)     613 (11.2)       1562 (17.5)        2191 (26.4)      \<0.01

   Poisoning                     566 (2.5)       140 (2.6)        269 (3.0)          157 (1.9)        \<0.01

   Renal disease                 922 (4.1)       232 (4.2)        372 (4.2)          318 (3.8)        0.21

   Sepsis                        1901 (8.4)      465 (8.5)        672 (7.5)          764 (9.2)        0.05

   Trauma                        1082 (4.8)      303 (5.5)        399 (4.5)          380 (4.6)        0.02

  CRRT use                       3579 (15.8)     750 (13.7)       1449 (16.3)        1380 (16.6)      \<0.01

  MV duration (days)             4.1 (2--10)     1.0 (0.3--1.1)   3.3 (2.3--5.0)     13.1 (9.1--21)   \<0.01

  ICU length of stay (days)      7 (3--15)       2 (1--4)         5 (3--8)           17 (11--28)      \<0.01

  Hospital stay (days)           19 (8--49)      6 (2--18.5)      15 (6--36)         36 (20--82)      \<0.01

  In-hospital mortality          12 936 (57.0)   3747 (68.4)      4474 (50.3)        4715 (56.8)      \<0.01
  ---------------------------------------------------------------------------------------------------------------

Data presented as n (%) or median (IQR). Only age presented as mean (SD).

\*P-value by Χ^2^ or Fisher's exact test for categorical variables, by analysis of variance for age and by Kruskal-Wallis test for other continuous variables.

CRRT, continuous renal replacement therapy; ICU, intensive care unit; MV, mechanical ventilation.

Analysis of medications based on MV duration {#s3b}
--------------------------------------------

Administration of medications classified as sedatives, analgesics, NMBAs and antipsychotics, based on MV duration are shown in [table 2](#T2){ref-type="table"}. Among 22 677 patients, 77.2% were administered sedative drugs and 50.6% used opioids during their ICU stays. The proportions of patients administered medications significantly increased in proportion to MV duration in all drug classes (p\<0.01, respectively). However, the percentages of person-days showed decreasing trends with greater MV duration, with the exception of antipsychotics. Midazolam was the most commonly used sedative drug (62.0%). The proportion of opioid use increased with MV duration (41.1% in MV\<48 hours, 47.5% in 48 hours≤MV\<7 days and 60.2% in MV≥7 days, p\<0.001). Among routes of administration, intravenous infusion including bolus increased with longer MV duration while enteral or topical applications decreased with daily MED dose (p\<0.01, respectively). Non-opioid analgesics were used in 34.0% of patients. Among 11 477 patients who used opioids, 38.7% were administered non-opioid analgesics simultaneously. The proportion of patients concomitantly administered opioid combined with non-opioid analgesics was significantly increased by 25.0%, 27.3% and 35.0% in the MV\<48 hours, 48 hours≤MV\<7 days, and MV≥7 days, respectively ([figure 2](#F2){ref-type="fig"}). NMBA was administered to 6593 patients (29.1%) for a median of 2 days (IQR 1--4). Antipsychotic medications were used in 4444 patients (19.6%). Within the MV ≥7 days group, one of four patients used antipsychotic medications, with increased percentages of person-days (p\<0.01).

###### 

Use of critical care medications classified by the duration of mechanical ventilation

  ------------------------------------------------------------------------------------------------------------------
  MV durations            Total\             MV\<48 hours\      48hrs≤MV\<7 days\   MV≥7 days (n=8294)   P value\*
                          (n=22 677)         (n=5480)           (n=8903)                                 
  ----------------------- ------------------ ------------------ ------------------- -------------------- -----------
  Analgo-sedatives        19 941 (87.9)      4143 (75.6)        7886 (88.6)         7912 (95.4)          \<0.01

  Sedatives               17 513 (77.2)      3186 (58.1)        6909 (77.6)         7418 (89.4)          \<0.01

   Days of use            4 (2--9)           2 (1--3)           3 (1--6)            7 (3--15)            \<0.01

   % person days          45.1 (40.3)        43.5 (44.9)        47.8 (40.0)         43.4 (37.0)          \<0.01

   Midazolam              14 069 (62.0)      2196 (40.1)        5406 (60.7)         6467 (78.0)          \<0.01

   Lorazepam              5980 (26.4)        871 (15.9)         2163 (24.3)         2946 (35.5)          \<0.01

   Propofol               323 (1.4)          52 (0.9)           112 (1.3)           159 (1.9)            \<0.01

  Analgesics total        14 744 (65.0)      2921 (53.3)        5499 (61.8)         6324 (76.2)          \<0.01

  Opioid analgesics       11 477 (50.6)      2254 (41.1)        4227 (47.5)         4996 (60.2)          \<0.01

   Days of use            3.0 (1--10)        2 (1--6)           3 (1--7)            5 (2--14)            \<0.01

   % person days          28.1 (38.6)        32.6 (43.8)        28.5 (38.7)         24.6 (34.1)          \<0.01

    Daily MED (mg)        23.8 (9.3--85.2)   23.3 (10--78.3)    25.0 (9.0--88.7)    23.1 (9.3--87.2)     0.86

   Intravenous            10 760 (47.4)      2107 (38.4)        3942 (44.3)         4711 (56.8)          \<0.01

    Daily MED (mg)        15.7 (8.3--60)     15.2 (8.3--46.4)   15.4 (8.3--54)      15.7 (8.25--78.5)    \<0.01

   Enteral                2635 (11.6)        512 (9.3)          1016 (11.4)         1107 (13.3)          \<0.01

    Daily MED (mg)        16.0 (9.6--40)     32.5 (12.5--90)    20.0 (10--56.3)     13.3 (7.5--22.2)     \<0.01

   Topical                1473 (6.5)         233 (4.3)          509 (5.7)           731 (8.8)            \<0.01

    Daily MED (mg)        50.0 (30--80)      60.0 (30--151.2)   50.0 (30--90)       45.0 (30--60)        \<0.01

   Morphine               3932 (17.3)        646 (11.8)         1352 (15.2)         1934 (23.3)          \<0.01

   Fentanyl               2683 (11.8)        414 (7.6)          973 (10.9)          1296 (15.6)          \<0.01

   Remifentanil           742 (3.3)          103 (1.9)          269 (3.0)           370 (4.5)            \<0.01

   Pethidine              3238 (14.3)        628 (11.5)         1081 (12.1)         1529 (18.4)          \<0.01

  Non-opioid analgesics   7713 (34.0)        1398 (25.5)        2772 (31.1)         3543 (42.7)          \<0.01

   Days of use            4 (1--15)          3 (1--12)          4 (1--12)           5 (2--19)            \<0.01

   % person days          19.7 (35.7)        20.2 (38.1)        20.1 (36.2)         18.8 (33.4)          \<0.01

   AAP or NSAIDs          6089 (26.9)        1091 (19.9)        2131 (23.9)         2867 (34.6)          \<0.01

   Anticonvulsants        2821 (12.4)        511 (9.3)          1026 (11.5)         1284 (15.5)          \<0.01

  NMBAs                   6593 (29.1)        868 (15.8)         2394 (26.9)         3331 (40.2)          \<0.01

   Days of use            2 (1--4)           1 (1--2)           1 (1--3)            3 (1--6)             \<0.01

   % person days          11.3 (25.3)        11.5 (29.9)        12.2 (26.3)         10.2 (20.6)          \<0.01

   Vecuronium             4189 (18.5)        511 (9.3)          1450 (16.3)         2228 (26.9)          \<0.01

   Rocuronium             831 (3.7)          105 (1.9)          331 (3.7)           395 (4.8)            \<0.01

   Cisatracurium          1614 (7.1)         153 (2.8)          568 (6.4)           893 (10.8)           \<0.01

  Antipsychotics          4444 (19.6)        610 (11.1)         1683 (18.9)         2151 (25.9)          \<0.01

   Days of use            6 (2--19)          4 (1--15)          5 (2--18)           7 (2--21)            \<0.01

   % person days          11.2 (28.5)        8.1 (25.6)         12.2 (30.1)         12.1 (28.5)          \<0.01

   Haloperidol            2528 (11.1)        336 (6.1)          933 (10.5)          1259 (15.2)          \<0.01

   Quetiapine             2567 (11.3)        321 (5.9)          941 (10.6)          1305 (15.7)          \<0.01

   Risperidone            538 (2.4)          73 (1.3)           203 (2.3)           262 (3.2)            \<0.01
  ------------------------------------------------------------------------------------------------------------------

Data presented as n (%) or as median (IQR). Only % person-days presented as mean (SD).

\*P-value by Χ^2^ or Fisher's exact tests for categorical variables, and by Kruskal-Wallis test for continuous variables.

AAP, acetaminophen; MED, morphine-equivalent dose; MV, mechanical ventilation; NMBA, neuromuscular blocking agent; NSAID, non-steroidal anti-inflammatory drug.

![Concomitant use of opioid and non-opioid analgesics in analgesic groups based on the duration of MV. The proportions of patients administered opioid and non-opioid simultaneously increased with MV duration whereas those of opioid-only and non-opioid-only decreased (p\<0.01). Data are indicated as numbers of patients with proportions in brackets. MV, mechanical ventilation.](bmjopen-2018-026605f02){#F2}

[Table 3](#T3){ref-type="table"} shows the association between patient demographics or clinical variables, and sedative or opioid use. Male sex, longer MV duration, CRRT application, longer ICU stay and admission via the emergency department were related to higher prescriptions of sedatives, whereas older age was related to a lower use of sedatives. For opioids, longer MV duration, CRRT application and longer ICU stay were related to higher use. Male sex was related to lower opioid prescriptions.

###### 

Demographic and clinical variables associated with uses of sedatives and opioids

                                     Sedatives use (n=17 513)   Opioids use (n=11 477)
  ---------------------------------- -------------------------- ------------------------
  Age, years (vs 65--74)             1                          1
   75--79                            0.91 (0.83 to 0.99)        0.94 (0.88 to 1.01)
   80 or more                        0.72 (0.66 to 0.78)        0.81 (0.76 to 0.86)
  Male sex                           1.36 (1.27 to 1.46)        0.92 (0.87 to 0.98)
  MV duration (vs MV\<48 hours)      1                          1
   48hrs≤MV\<7 days                  2.20 (2.03 to 2.37)        1.24 (1.16 to 1.33)
   MV≥7 days                         3.43 (3.07 to 3.84)        1.64 (1.51 to 1.79)
  CRRT apply                         1.16 (1.06 to 1.28)        1.64 (1.52 to 1.77)
  Administration route (Emergency)   1.14 (1.06 to 1.22)        0.96 (0.91 to 1.02)
  Primary disease                                               
   Cardiac disease                   0.83 (0.75 to 0.92)        0.96 (0.88 to 1.04)
   Cerebrovascular disease           0.52 (0.47 to 0.57)        0.51 (0.46 to 0.56)
   Chronic pulmonary disease         2.09 (1.72 to 2.53)        1.14 (1.01 to 1.29)
   Gastrointestinal                  0.89 (0.67 to 1.19)        2.10 (1.62 to 2.73)
   Liver disease                     0.59 (0.44 to 0.80)        1.11 (0.84 to 1.45)
   Malignancy                        1.20 (1.05 to 1.36)        2.44 (2.20 to 2.71)
   Pneumonia                         1.26 (1.14 to 1.39)        0.96 (0.89 to 1.03)
   Poisoning                         1.26 (1.01 to 1.57)        0.58 (0.49 to 0.70)
   Renal disease                     0.67 (0.56 to 0.80)        0.97 (0.83 to 1.12)
   Sepsis                            0.86 (0.76 to 0.97)        0.92 (0.84 to 1.02)
   Trauma                            0.68 (0.59 to 0.79)        1.46 (1.29 to 1.66)
  Length of ICU stay (continuous)    1.03 (1.03 to 1.04)        1.02 (1.01 to 1.02)

CRRT, continuous renal replacement therapy; ICU, intensive care unit; MV, mechanical ventilation.

[Table 4](#T4){ref-type="table"} shows the patterns of the combined use of sedatives, analgesics, NMBAs and antipsychotics classified by duration of MV. Among 22 677 patients, 89.1% were prescribed at least one medication during MV application. The proportion of patients administered medications in combination significantly increased with MV duration (45.3% in MV\<48 hours, 64.5% in 48 hours≤MV\<7 days and 81.3% in MV ≥7 days, p\<0.01).

###### 

Patterns of the combined use of study drugs classified by the duration of mechanical ventilation

  ----------------------------------------------------------------------------------------------------
  MV durations                            MV\<48 hours\   48hrs≤MV\<7days\   MV≥7 days\    P value\*
                                          (n=5480)        (n=8903)           (n=8294)      
  --------------------------------------- --------------- ------------------ ------------- -----------
  Number of drug classes in combination                                                    \<0.01

   0                                      1257 (22.9)     894 (10.0)         320 (3.9)     

   1                                      1740 (31.8)     2263 (25.4)        1229 (14.8)   

   2                                      1687 (30.8)     3382 (38.0)        3132 (37.8)   

   3                                      713 (13.0)      1998 (22.4)        2721 (32.8)   

   4                                      83 (1.5)        366 (4.1)          892 (10.8)    

  Sedatives                               3186            6909               7418          

   Used in combination with:                                                               

    Analgesics                            1964 (61.6)     4522 (65.5)        5830 (78.6)   \<0.01

    NMBAs                                 501 (15.7)      1532 (22.2)        2071 (27.9)   \<0.01

    Antipsychotics                        723 (22.7)      2206 (31.9)        3225 (42.4)   \<0.01

  Analgesics                              2921            5499               6324          

   Used in combination with:                                                               

    Sedatives                             1964 (67.2)     4522 (82.2)        5830 (92.2)   \<0.01

    NMBAs                                 560 (19.2)      1579 (28.7)        2673 (42.3)   \<0.01

    Antipsychotics                        466 (16.0)      1239 (22.5)        1811 (28.6)   \<0.01

  NMBAs                                   868             2394               3331          

   Used in combination with:                                                               

    Analgesics                            560 (64.5)      1579 (66.0)        2673 (80.3)   \<0.01

    Sedatives                             723 (83.3)      2206 (92.2)        3225 (96.8)   \<0.01

    Antipsychotics                        110 (12.7)      494 (20.6)         1037 (31.1)   \<0.01

  Antipsychotics                          610             1683               2151          

   Used in combination with:                                                               

    Analgesics                            466 (76.4)      1239 (73.6)        1811 (84.2)   \<0.01

    Sedatives                             501 (82.1)      1532 (91.0)        2071 (96.3)   \<0.01

    NMBAs                                 110 (18.0)      494 (37.9)         1037 (48.4)   \<0.01
  ----------------------------------------------------------------------------------------------------

\*P-value by Χ ^2^ test.

MV, mechanical ventilation; NMBA, neuromuscular blocking agent.

Analysis of medication use based on age {#s3c}
---------------------------------------

The current practices of medication administration in elderly patients based on age groups (65≤age\<75 years, 75≤age\<80 years and 80 years or more) are shown in [table 5](#T5){ref-type="table"}. The prescriptions of sedatives, analgesics and NMBAs decreased with increasing age (80.1%, 78.3% and 73.6% for sedatives in patients 65≤age\<75 years, 75≤age\<80 years and 80 years or more; 68.7%, 65.9% and 60.6% for analgesics; and 33.5%, 30.3% and 23.6% for NMBAs, p\<0.01 respectively). The proportions of patients who did not require any medications were 9.0% in those 65≤age\<75 years, 10.7% in those 75≤age\<80 years and 13.0% in those over 80 years of age (p\<0.01).

###### 

Use of critical care medications classified by patient age groups

  ------------------------------------------------------------------------------------------------------
  Age groups (years)            65≤Age\<75 years\   75≤Age\<80 years\    Age≥80 years\       P value\*
                                (n=8551)            (n=5813)             (n=8313)            
  ----------------------------- ------------------- -------------------- ------------------- -----------
  No use of study medications   773 (9.0)           620 (10.7)           1078 (13.0)         \<0.01

  Analgo-sedatives              7701 (90.1)         5131 (88.3)          7109 (85.5)         \<0.01

  Sedatives                     6846 (80.1)         4550 (78.3)          6117 (73.6)         \<0.01

   Days of use                  4 (2--10)           4 (2--9)             3 (1--8)            \<0.01

   Midazolam                    5625 (65.8)         3686 (63.4)          4758 (57.2)         \<0.01

   Lorazepam                    2398 (28.0)         1573 (27.1)          2009 (24.2)         \<0.01

   Propofol                     138 (1.6)           91 (1.6)             94 (1.1)            0.01

  Analgesics total              5871 (68.7)         3832 (65.9)          5041 (60.6)         \<0.01

  Opioid analgesics             4627 (54.1)         2985 (51.4)          3865 (46.5)         \<0.01

   Daily MED (mg)               26.1 (10.0--92.5)   23.3 (9.0--85.0)     21.5 (8.3--74.0)    \<0.01

   Intravenous                  4348 (50.8)         2781 (47.8)          3631 (43.7)         \<0.01

    Daily MED (mg)              15.7 (8.3--60.1)    15.7 (8.3--60.0)     15.0 (8.3--60.0)    0.03

   Enteral                      1147 (13.4)         681 (11.7)           807 (9.7)           \<0.01

    Daily MED (mg)              15.9 (9.6--41.3)    16.5 (10.0--38.2)    16.0 (9.4--39.4)    0.87

   Topical                      678 (7.9)           360 (6.2)            435 (5.2)           \<0.01

    Daily MED (mg)              60.0 (30.0--90.0)   48.0 (30.0--100.0)   37.5 (30.0--60.0)   \<0.01

   Morphine                     1692 (19.8)         1008 (17.3)          1232 (14.8)         \<0.01

   Fentanyl                     1169 (13.7)         674 (11.6)           840 (10.1)          \<0.01

   Remifentanil                 278 (3.3)           193 (3.3)            271 (3.3)           0.97

   Pethidine                    1401 (16.4)         855 (14.7)           982 (11.8)          \<0.01

  Non-opioid analgesics         3097 (36.2)         1983 (34.1)          2633 (31.7)         \<0.01

   Days of use                  4 (2--17)           4 (1--16)            4 (1--13)           \<0.01

   AAP or NSAIDs                2414 (28.2)         1574 (27.1)          2101 (25.3)         \<0.01

   Anticonvulsants              1214 (14.2)         737 (12.7)           870 (10.5)          \<0.01

  NMBAs                         2867 (33.5)         1764 (30.3)          1962 (23.6)         \<0.01

   Days of use                  2 (1--4)            2 (1--4)             2 (1--3)            \<0.01

   Vecuronium                   1797 (21.0)         1118 (19.2)          1274 (15.3)         \<0.01

   Rocuronium                   358 (4.2)           224 (3.9)            249 (3.0)           \<0.01

   Cisatracurium                751 (8.8)           461 (7.9)            402 (4.8)           \<0.01

  Antipsychotics                1722 (20.1)         1129 (19.4)          1593 (19.2)         0.11

   Days of use                  5 (2--18)           6 (2--19)            6 (2--20)           0.34

   Haloperidol                  1034 (12.1)         628 (10.8)           866 (10.4)          \<0.01

   Quetiapine                   961 (11.2)          657 (11.3)           949 (11.4)          0.72

   Risperidone                  201 (2.4)           129 (2.2)            208 (2.5)           0.52
  ------------------------------------------------------------------------------------------------------

Data presented as n (%) or as median (IQR).

Annual trends in the administration of sedative, analgesic, NMBA and antipsychotic medications.

\*P-value by Χ ^2^ or Fisher's exact tests for categorical variables, and by Kruskal-Wallis test for other continuous variables.

AAP, acetaminophen; MED, morphine-equivalent dose; MV, mechanical ventilation; NMBA, neuromuscular blocking agent; NSAID, non-steroidal anti-inflammatory drug.

However, antipsychotic use showed no significant change based on age groups, at 20.1% in those 65≤age\<75 years, 19.4% in those 75≤age\<80 years and 19.2% in those aged 80 years or more (p=0.11). When adjusting for sex, MV duration, disease status and duration of ICU stay, the adjusted ORs (95% CI) for sedative, analgesic, NMBA and antipsychotics use were 0.98 (0.97 to 0.98), 0.98 (0.97 to 0.98), 0.98 (0.97 to 0.98) and 1.00 (1.00 to 1.01), respectively).

Annual differences in medication use are presented in [table 6](#T6){ref-type="table"}. Sedative drugs, especially benzodiazepines (mainly midazolam and lorazepam), showed reduced annual administration (76.2% in 2012, 75.6% in 2013, 73.6% in 2014, 72.6% in 2015 and 71.4% in 2016, p\<0.01). There were no changes in the ratios of patients who used opioids annually, while the median daily doses of opioids increased from 2012 to 2016 (21.6, 22.4, 21.3, 26.0 and 30.0 mg, p\<0.01). Among opioids, fentanyl and remifentanil use increased, while morphine and pethidine use decreased during the same period. Among non-opioid analgesics, AAPs and NSAIDs showed decreased use. The results showed increasing use of NMBAs and antipsychotic agents each year. For NMBAs, vecuronium usage decreased, while cisatracurium and rocuronium use increased.

###### 

Annual trends in the use of critical care medications in elderly, 2012--2016

  ----------------------------------------------------------------------------------------------------------------------------------------
  Year                    2012\               2013\                2014\               2015\               2016\               P value\*
                          (n=4642)            (n=4478)             (n=4513)            (n=4588)            (n=4456)            
  ----------------------- ------------------- -------------------- ------------------- ------------------- ------------------- -----------
  Analgo-sedatives        4129 (89.0)         3972 (88.7)          3940 (87.3)         4010 (87.4)         3890 (87.3)         \<0.01

  Sedatives               3679 (79.3)         3511 (78.4)          3440 (76.2)         3516 (76.6)         3367 (75.6)         \<0.01

   Days of use            4 (2--10)           4 (2--9)             4 (2--9)            3 (2--8)            3 (2--8)            \<0.01

   Midazolam              2947 (63.5)         2822 (63.0)          2798 (62.0)         2801 (61.1)         2701 (60.6)         \<0.01

   Lorazepam              1385 (29.8)         1260 (28.1)          1180 (26.1)         1150 (25.1)         1005 (22.6)         \<0.01

   Propofol               72 (1.6)            58 (1.3)             54 (1.2)            57 (1.2)            82 (1.8)            0.37

  Analgesics total        3060 (65.9)         2956 (66.0)          2893 (64.1)         2924 (63.7)         2911 (65.3)         0.12

  Opioid analgesics       2308 (49.7)         2276 (50.8)          2299 (50.9)         2292 (50.0)         2302 (51.7)         0.20

   Daily MED (mg)         21.6 (9.6--71.5)    22.4 (9.1--69.4)     21.3 (8.8--72.5)    26.0 (9.6--88.3)    30.0 (9.9--147.7)   \<0.01

   Intravenous            532 (11.5)          542 (12.1)           529 (11.7)          525 (11.4)          507 (11.4)          \<0.01

   Daily MED (mg)         15.0 (8.3--49.5)    15.7 (8.3--51.3)     15.0 (8.3--52.5)    15.7 (8.3--60.0)    16.5 (8.3--115.6)   \<0.01

   Enteral                2161 (46.6)         2126 (47.5)          2162 (47.9)         2133 (46.5)         2178 (48.9)         0.12

   Daily MED (mg)         15.0 (10.0--36.6)   16.2 (9.5--42.5)     15.2 (10.0--37.6)   16.9 (9.8--41.4)    16.7 (8.4--39.6)    0.88

   Topical                272 (5.9)           283 (6.3)            286 (6.3)           328 (7.1)           304 (6.8)           0.02

   Daily MED (mg)         60.0 (30.0--90.0)   54.0 (30.0--108.0)   51.3 (30.0--80.0)   32.1 (30.0--60.0)   47.6 (30.0--87.0)   \<0.01

   Morphine               880 (19.0)          825 (18.4)           813 (18.0)          747 (16.3)          667 (15.0)          \<0.01

   Fentanyl               495 (10.7)          528 (11.8)           503 (11.1)          607 (13.2)          550 (12.3)          \<0.01

   Remifentanil           70 (1.5)            87 (1.9)             104 (2.3)           124 (2.7)           357 (8.0)           \<0.01

   Pethidine              699 (15.1)          674 (15.1)           652 (14.4)          619 (13.5)          594 (13.3)          \<0.01

  Non-opioid analgesics   1658 (35.7)         1536 (34.3)          1455 (32.2)         1439 (31.4)         1625 (36.5)         0.46

   Days of use            4 (1--12)           4 (1--14)            4 (1--17)           4 (1--15)           5 (2--18)           \<0.01

   AAP or NSAIDs          1400 (30.2)         1212 (27.1)          1135 (25.1)         1123 (24.5)         1219 (27.4)         \<0.01

   Anticonvulsants        526 (11.3)          581 (13.0)           557 (12.3)          532 (11.6)          625 (14.0)          0.01

  NMBAs                   1275 (27.5)         1247 (27.8)          1241 (27.5)         1310 (28.6)         1520 (34.1)         \<0.01

   Days of use            2 (1--4)            2 (1--4)             2 (1--4)            2 (1--4)            2 (1--3)            \<0.01

   Vecuronium             998 (21.5)          903 (20.2)           779 (17.3)          748 (16.3)          761 (17.1)          \<0.01

   Rocuronium             94 (2.0)            115 (2.6)            134 (3.0)           211 (4.6)           277 (6.2)           \<0.01

   Cisatracurium          152 (3.3)           279 (6.2)            364 (8.1)           446 (9.7)           373 (8.4)           \<0.01

  Antipsychotics          785 (16.9)          803 (17.9)           928 (20.6)          967 (21.1)          961 (21.6)          \<0.01

   Days of use            5 (2--17)           6 (2--21)            6 (2--18)           6 (1--20)           6 (2--20)           0.45

   Haloperidol            478 (10.3)          466 (10.4)           523 (11.6)          557 (12.1)          504 (11.3)          0.01

   Quetiapine             368 (7.9)           453 (10.1)           558 (12.4)          568 (12.4)          620 (13.9)          \<0.01

   Risperidone            112 (2.4)           104 (2.3)            96 (2.1)            108 (2.4)           118 (2.6)           0.49
  ----------------------------------------------------------------------------------------------------------------------------------------

Data presented as n (%) or as median (IQR).

\*P-value by Χ^2^ or Fisher's exact tests for categorical variables, and by Kruskal-Wallis test for other continuous variables.

AAP, acetaminophen; MED, morphine-equivalent dose; NMBA, neuromuscular blocking agent; NSAID, non-steroidal anti-inflammatory drug.

Discussion {#s4}
==========

In this population-based study of critically ill elderly patients, 87.9% patients were administered more than one analgo-sedative during their ICU stay. Sedatives were administered in 77.2% of the study population and midazolam was the most commonly used medication (62.0%). Longer MV duration increased the usage of sedatives, analgesics and NMBAs; however, the percentage of person-days decreased. However, the prevalence and person-days for antipsychotic prescriptions increased with MV duration and did not decrease with age. The proportion of patients who did not require any medications increased with advanced age (p\<0.01).

Overall, our analysis showed annual trends partially in line with recent recommendations in adult patients, especially within each class of medications as well as decreased use of medications with safety issues and increased use of medications with fewer adverse effects and complications. Although midazolam was the most commonly used medication in this study, the significant annual reduction of benzodiazepines (76.2%, 75.6%, 73.6%, 72.6% and 71.4% from 2012 to 2016, p\<0.01) and increased use of opioids (increased daily MEDs with even proportions) reflected analgesia-based sedation.[@R2] Among opioids, the use of pethidine, which is not recommended for analgesia in the ICU due to its potential for neurologic side effects,[@R5] significantly decreased, whereas remifentanil use increased over time (p\<0.01). Vecuronium use decreased among NMBAs, while cisatracurium and rocuronium use increased (p\<0.01) from 2012 to 2016. Cisatracurium is preferred in critically ill patients due to its pharmacological characteristics including the low risks of renal and hepatic failure.[@R13] Within the same period, NMBAs showed increased administration; however, the median duration of total usage was concentrated within 48 hours (2.0 days, IQR 1--4). This may reflect current guideline recommendations to use NMBAs in the early MV period within 48 hours.[@R14]

In contrast, the present study had several unique findings in elderly patients compared with the general guidelines for adults. First, in this elderly population, the daily MED of opioid was lower and the prevalence of antipsychotics use was higher compared with those in previous studies of adult ICU patients. The daily median MEDs of opioids in the present study were 23.8 mg (IQR 9.3--85.2) (23.3 mg median MED in MV≤48 hours, 25.0 mg in 48 hours\<MV\<7 days and 23.1 mg in MV≥7 days); in comparison, Burry *et al* [@R15] reported mean MEDs of 23.2 mg for MV≤48 hours, 62.9 mg for 48 hours\<MV\<7 days and 106.0 mg for MV≥7 days. The administration of antipsychotics in the present study (20.1% in 65≤age\<75 years, 19.4% in 75≤age\<80 years and 19.2% in ≥80 years) was higher than that in the Burry study (9.6%). This difference may be due to a difference in age distribution between the studies (mean 77.2±6.9 years in this study and 60.8±16.7 years in the Burry study) which reflects the cautious use of opioids considering potential safety concerns and potentially higher prevalence of delirium in elderly patients. Compared with antipsychotic prescription, the relatively low prevalence of delirium in the present study could be due to an under-reporting of diagnostic codes in a clinical setting. The prevalence of delirium is easily underestimated without applying organised evaluation tools.[@R2] Burry *et al* also discussed the low assessment of delirium along with the gap between actual clinical practice and expectations.[@R15] Propofol also showed a relatively lower prevalence and decreased use with increasing age in our study. Payer *et al* reported propofol as the second most commonly used sedative (20% in 44 French ICUs).[@R16] The relatively lower use of propofol in this study might be due to concerns over adverse effects in Korea, such as propofol infusion syndrome,[@R17] as well as old age. Dundee reported a relatively sensitive response in the elderly, with reduced requirement of induction dose and marked hypotension and apnea.[@R18]

Second, the proportions of patients administered single-drug or multi-drug classes in combination significantly increased with MV duration (p\<0.01) ([table 4](#T4){ref-type="table"}). Among those administered sedatives, 61.6% of patients in the MV\<48 hours group used analgesics simultaneously, compared with 65.5% and 78.6% in the 48 hours≤MV\<7 days and in MV≥7 days groups (p\<0.01). Patients administered benzodiazepines showed higher rates of antipsychotic use in combination than that in the non-benzodiazepine group (24.0% vs 7.0%, p\<0.01). The proportion of patients with delirium was higher in the benzodiazepine group (0.35%) than that in the non-benzodiazepine group (0.08%) (p\<0.01). The administration of benzodiazepines was related to an increased risk of delirium and increased use of antipsychotics. Stollings *et al* reported that the plasma concentration of lorazepam was associated with delirium and that avoidance of benzodiazepines may result in the reduced risk of delirium.[@R19]

An advantage of the present study is its inclusion of extensive medications within the analysis (online [supplementary table 1](#SP1){ref-type="supplementary-material"}). The use of non-opioid analgesics, including AAPs, NSAIDs and anticonvulsants used for neuropathic pain,[@R20] were analysed in conjunction with opioids. Opioids are initial analgesics for critically ill patients; however, non-opioid analgesics can reduce opioid dose and lower the risks of complications. Among 11 477 patients who used opioids, 4446 (38.7%) were administered non-opioid analgesics simultaneously. Patients administered both opioid and non-opioid analgesics had significantly lower daily doses of opioids than those administered only opioids (median daily MED 23.3 mg (IQR 10.0--79.8) in combined administration vs 24.4 mg (IQR 9.0--90.0) for opioid only, p\<0.01), which may reflect a reduction in opioid requirements.

The study has several limitations. We could not assess the degrees of sedation, pain, or delirium in comparison with medications and clinical severity scores because these data were not available in the claims database. In addition, we could not identify a causal relationship between sedative drug use and clinical outcomes. Although current guidelines suggest dexmedetomidine instead of benzodiazepines[@R21] and reduced proportion of patients who used benzodiazepines in our population could be moved to dexmedetomidine, we could not determine the use of dexmedetomidine because it is not covered by national insurance in Korea. Despite these limitations, this study demonstrates real-world practice patterns using a nationally representative database of critically ill elderly patients under MV.[@R22]

Conclusions {#s5}
===========

Annual trends in reduced use of sedatives including benzodiazepines and increased opioid daily dose reflecting the analgesia-based sedation principle were observed in elderly critical care patients. However, a lower prevalence of sedative, analgesic and NMBA use was observed for advanced age groups with relatively lower daily opioid dose, lower prescriptions of propofol and higher prevalences of antipsychotic use compared with previous studies on adult ICU patients. Further studies investigating appropriateness and safety of medication use that consider clinical severity scores in elderly critical care patients are required to develop elderly specific patient guidelines on the usage of sedatives, analgesics, NMBAs and antipsychotics.
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